Temperature-Stable Experimental Tuberculosis Vaccine Enters Clinical Testing

An NIAID-supported Phase 1 clinical trial testing a freeze-dried, temperature stable formulation of an experimental TB vaccine regimen is ongoing at the Saint Louis University School of Medicine Center for Vaccine Development. The experimental vaccine, called ID93, was developed by scientists at the Infectious Disease Research Institute in Seattle. Investigators are examining if a powder formulation combining the vaccine and the adjuvant GLA-SE in a single vial, reconstituted with sterile water, is as effective at inducing an immune response in participants as the previously-tested two-vial combination of powdered ID93 and liquid GLA-SE.